Overview

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Status:
Not yet recruiting

Trial end date:
2024-02-16

Target enrollment:

Participant gender:

Summary

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab
Gemcitabine
Paclitaxel